Veracyte registers 1,016,965 shares for resale relating to C2i Genomics acquisition

VERACYTE, INC.

Filed prospectus supplement to register 1,016,965 shares of common stock for resale.
Shares were issued as part of the consideration for the February 5, 2024 acquisition of C2i Genomics.
Legal opinion from Fenwick & West LLP regarding the legality of the registered shares filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.